Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	33,047	39,034	24,243	18,858	24,266	14,979
Market Cap Growth	16.08%	61.01%	28.56%	-22.29%	62.00%	35.43%
Enterprise Value	33,091	39,070	24,200	19,060	24,537	14,677
Last Close Price	252.22	298.86	190.55	151.59	191.34	119.22
PE Ratio	141.76	167.44	-	-	-	-
PS Ratio	11.98	14.15	13.50	13.14	28.18	24.02
PB Ratio	56.36	66.57	452.40	-108.87	-184.79	34.48
P/TBV Ratio	56.36	66.57	452.40	-	-	34.48
P/FCF Ratio	95.57	112.89	-	572.67	-	-
P/OCF Ratio	84.87	100.24	-	230.62	-	-
EV/Sales Ratio	12.02	14.16	13.48	13.28	28.50	23.54
EV/EBITDA Ratio	70.69	94.37	-	-	-	-
EV/EBIT Ratio	89.01	104.84	-	-	-	-
EV/FCF Ratio	95.70	112.99	-	578.81	-	-
Debt / Equity Ratio	3.76	3.76	40.89	-12.16	-16.51	3.72
Debt / EBITDA Ratio	4.70	4.70	-	-	-	-
Debt / FCF Ratio	6.38	6.38	-	63.96	-	-
Net Debt / Equity Ratio	0.08	0.08	0.73	-1.10	-2.65	-0.42
Net Debt / EBITDA Ratio	0.11	0.11	-0.41	-1.07	-0.57	0.38
Net Debt / FCF Ratio	0.13	0.13	-1.15	5.80	-0.68	0.35
Asset Turnover	0.81	0.81	0.56	0.50	0.29	0.24
Inventory Turnover	8.46	8.46	3.86	2.85	1.57	1.74
Quick Ratio	2.51	2.51	2.61	2.86	3.17	3.79
Current Ratio	2.76	2.76	2.78	3.08	3.51	4.04
Return on Equity (ROE)	73.28%	73.28%	-	-	-526.14%	-106.31%
Return on Assets (ROA)	6.81%	6.81%	-2.74%	-4.78%	-13.65%	-12.56%
Return on Invested Capital (ROIC)	86.03%	100.88%	-255.24%	-198.35%	-261.58%	-132.10%
Return on Capital Employed (ROCE)	14.30%	14.30%	-5.80%	-9.90%	-28.30%	-24.00%
Earnings Yield	0.71%	0.60%	-0.92%	-1.83%	-3.87%	-4.21%
FCF Yield	1.05%	0.89%	-0.14%	0.18%	-2.10%	-3.54%
Buyback Yield / Dilution	-5.51%	-5.51%	-2.20%	-2.64%	-2.73%	-3.01%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.